Sarepta Therapeutics (AB3A) Ownership - Who Owns Sarepta Therapeutics?
Sarepta Therapeutics (AB3A) Ownership Overview
- 6.08% Insiders
- 20.45% Mutual Funds
- 0.54% Other Institutional Investors
- 31.24% ETFs
- 41.70% Public Companies and Individual Investors
The ownership structure of Sarepta Therapeutics (DE:AB3A) stock is a mix of institutional, retail, and individual investors. Approximately 52.22% of the company’s stock is owned by Institutional Investors, 6.08% is owned by Insiders, and 41.70% is owned by Public Companies and Individual Investors.
The ownership structure of Sarepta Therapeutics (DE:AB3A) stock is a mix of institutional, retail, and individual investors. Approximately 52.22% of the company’s stock is owned by Institutional Investors, 6.08% is owned by Insiders, and 41.70% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Mar 12, 2026 | Stephen Mayo | $123,208 | |
| Dec 17, 2025 | Ian Michael Estepan | $294,202 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Wexford Capital Lp | €99,960 | |
| Dec 31, 2025 | Hussman Strategic Advisors Inc | €1,355,760 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | €6,037,823 | |
| Dec 31, 2025 | Highbridge Capital Management Llc | €8,608,000 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | Institution | 17.98% | 356,383,402 |
| Ishares | 12,604,234 | Institution | 11.93% | 236,480,638 |
| Vanguard | 9,684,643 | Institution | 9.17% | 181,703,272 |
| Vanguard Index Funds | 8,021,777 | Institution | 7.59% | 150,504,580 |
| Spdr | 5,207,120 | Institution | 4.93% | 97,695,985 |
| Peter Kolchinsky | 3,902,596 | Institution | 3.69% | 73,220,506 |
| Richard Barry | 3,233,542 | Insider | 3.06% | 60,667,715 |
| Vanguard Horizon Funds | 1,396,212 | Institution | 1.32% | 26,195,730 |
| Fidelity Salem Street Trust | 1,300,949 | Institution | 1.23% | 24,408,405 |
| Federated Hermes Equity Funds | 1,106,479 | Institution | 1.05% | 20,759,759 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 8,021,777 | Institution | 7.59% | 150,504,580 |
| Vanguard Horizon Funds | 1,396,212 | Institution | 1.32% | 26,195,730 |
| Fidelity Salem Street Trust | 1,300,949 | Institution | 1.23% | 24,408,405 |
| Federated Hermes Equity Funds | 1,106,479 | Institution | 1.05% | 20,759,759 |
| Fidelity Concord Street Trust | 1,019,776 | Institution | 0.97% | 19,133,037 |
| Vanguard Tax-managed Funds | 775,457 | Institution | 0.73% | 14,549,124 |
| Tiaa-cref Funds | 772,609 | Institution | 0.73% | 14,495,690 |
| Vanguard Scottsdale Funds | 704,143 | Institution | 0.67% | 13,211,131 |
| Vanguard Explorer Fund | 528,659 | Institution | 0.50% | 9,918,700 |
| Aqr Funds | 481,507 | Institution | 0.46% | 9,034,034 |
FAQ
Who Owns Sarepta Therapeutics (DE:AB3A)?
According to the latest TipRanks data, approximately 52.22% of the company's stock is held by institutional investors, 6.08% is held by insiders, and 41.70% is held by public companies and individual investors.
What percentage of Sarepta Therapeutics (DE:AB3A) stock is held by institutional investors?
According to the latest TipRanks data, approximately 52.22% of Sarepta Therapeutics (DE:AB3A) stock is held by institutional investors: 20.45% by mutual funds, 31.24% by ETFs and 0.54% by other institutional investors.
What percentage of Sarepta Therapeutics (DE:AB3A) stock is held by retail investors?
According to the latest TipRanks data, approximately 41.70% of Sarepta Therapeutics (DE:AB3A) stock is held by public companies and individual investors.
Who owns the most shares of Sarepta Therapeutics (DE:AB3A)?
BlackRock, Inc. owns the most shares of Sarepta Therapeutics (DE:AB3A).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
